
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is expected to increase revenue from the sale of its LungFit GO device for the treatment of respiratory diseases, particularly in the midst of a global pandemic. The termination of the deal with XTLBiopharmaceuticals for the NeuroNOS platform may lead to increased strategic exploration and operational focus on the core LungFit nitric oxide delivery franchise. Additionally, Beyond Air's financials show steady revenue growth and a strong potential for further growth in the future.
Bears say
Beyond Air is facing multiple risks, including potentially limited market potential for its products in niche markets, significant financial and capital risks, and potential challenges with commercialization and clinical development. Additionally, the company is dependent on third-parties for distribution and faces risks related to intellectual property, operations, and employees. These factors all contribute to a negative outlook for the company's stock given the high levels of uncertainty and potential for setbacks.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares